Physician profile
Dolon C Das
NPI 1619972692
$4,044.96
in general payments reported to CMS, 2019-2025
23 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $68.02 · 2021: $176 · 2022: $350 · 2023: $1,055 · 2024: $987 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,997 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,996.51 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $927.18 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals Lp | $475.67 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $467.72 | 2021-2025 | |
| Travere Therapeutics, INC. | $311.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $242.26 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $229.27 | 2023-2025 | Acthar |
| Genzyme Corporation | $224.52 | 2023 | |
| Aurinia Pharma U.S., INC. | $222.19 | 2022-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $167.08 | 2023-2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $147.20 | 2021-2024 | |
| Amgen INC. | $95.25 | 2019-2025 | Tavneos |
| Mallinckrodt Enterprises LLC | $89.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.65 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $74.83 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $66.08 | 2021-2023 | Veltassa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $53.85 | 2024-2025 | Rivfloza |
| Akebia Therapeutics INC | $42.38 | 2025 | Vafseo |
| Cormedix INC. | $30.54 | 2024 | Defencath |
| Calliditas Therapeutics US INC. | $23.83 | 2024 | |
| Lilly USA, LLC | $20.79 | 2025 | Jardiance |
| Cycle Pharmaceuticals INC | $17.65 | 2025 | Venxxiva |
| Horizon Therapeutics Plc | $17.14 | 2020 | |
| Merck Sharp & Dohme LLC | $16.50 | 2023 | Dificid, Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dolon Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.